CClinicalTrials.gg
Sign In
Status unknownNCT02118376Updated Apr 21, 2014

Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status

An interventional study of Exenatide in Obesity, sponsored by Shanghai 10th People's Hospital. Status unknown at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-04-21.

Sponsored by Shanghai 10th People's Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2013), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state

Read the detailed description

As a treatment for type 2 diabetesGlucagon like peptide -1 (Glucan-like peptide-1, GLP-1) receptor agonists plays the role of promoting insulin secretion, inhibiting glucagon secretion，and also has the central and peripheral effects,it can inhibit appetite,reduce weight.GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • obesity; fat distribution; inflammation
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's planned enrollment of 20 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Shanghai 10th People's Hospital is the lead sponsor of 167 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical diagnosis of overweight and type 2 diabetes mellitus

Exclusion criteria

Exclusion Criteria:

  • Poor body condition (severe liver and kidney dysfunction)
  • Unknown causes of pancreatitis, chronic pancreatitis, pancreatic resection, stomach operation, malignant tumor, previous use of systemic corticosteroids (local or inhalation of exceptions) heart function or niacin, incomplete
  • serious endocrine disease
  • genetic disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    exenatide

    exenatide, 5ug, bid, 3months

    Drug: Exenatide

Interventions

  • DrugExenatide

    5ug bid,Subcutaneous injection

    Also known as: Byetta

06

What researchers measure

Primary outcomes

  1. Dual energy X-ray absorptiometry

    fat distribution

    Time frame: 3 month

Secondary outcomes

  1. lab testing

    inflammation

    Time frame: 3 month

Other outcomes

  1. lab testing

    liver function

    Time frame: 3 months

07

Study locations

1 site
  • Shanghai Tenth People' Hospital
    Shanghai, Shanghai 200072, China
08

References and documents

Publications

  • Wang X, Chen J, Li L, Zhu CL, Gao J, Rampersad S, Bu L, Qu S. New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it. Lipids Health Dis. 2017 Apr 4;16(1):70. doi: 10.1186/s12944-017-0462-1. PubMed 28376799 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02118376
Lead sponsor
Shanghai 10th People's Hospital
Responsible party
Zhang Manna (Professor, Shanghai 10th People's Hospital) — Principal investigator
First posted
Apr 21, 2014
Start date
Aug 2014
Primary completion
Dec 2014 (estimated)
Completion
Dec 2014 (estimated)
Last update
Apr 21, 2014

Study contacts

Yu Jie
Contact
13916674766
Qu Shen
study director · Shang Tenth People's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Obesity→

Other studies from this sponsor

Shanghai 10th People's Hospital

Start the discussion